High Grade Glioma Clinical Trials

31 studies are recruiting for high grade glioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Columbus, Ohio 9 Philadelphia, Pennsylvania 8 Washington D.C., District of Columbia 8 Aurora, Colorado 7 Boston, Massachusetts 7 Chicago, Illinois 7 Cincinnati, Ohio 7 Houston, Texas 7 Miami, Florida 7 Durham, North Carolina 6 Seattle, Washington 6 New York, New York 4 Ann Arbor, Michigan 3

Studies, page 2

  1. Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

    This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gl…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Run by
    NYU Langone Health

    See if you can join NCT06829173 on ClinicalTrials.gov

  2. 18F-Fluciclovine PET-MRI in High-grade Glioma

    The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes th…

    Stage
    EARLY_Phase 1
    Ages
    1 to 21
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Run by
    Children's Hospital of Philadelphia

    See if you can join NCT05553041 on ClinicalTrials.gov

  3. Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

    An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of…

    Stage
    Phase 1
    Ages
    Up to 18
    Site
    Arkansas Children's Research Institute, Little Rock, Arkansas
    Locations
    3 in total
    Run by
    Laminar Pharmaceuticals

    See if you can join NCT04299191 on ClinicalTrials.gov

  4. A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

    This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be …

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Chandler Regional Medical Center, Chandler, Arizona
    Locations
    2 in total
    Run by
    St. Joseph's Hospital and Medical Center, Phoenix

    See if you can join NCT06072586 on ClinicalTrials.gov

  5. Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

    Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week. TGFβi NK cell infusions should be delivered at least 3 days apart (e.g., Friday of We…

    Stage
    Phase 1
    Ages
    1 to 39
    Site
    Nationwide Children's Hospital, Columbus, Ohio
    Run by
    Nationwide Children's Hospital

    See if you can join NCT04254419 on ClinicalTrials.gov

  6. The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

    A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). T…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    University of California, San Francisco (UCSF), San Francisco, California
    Locations
    8 in total
    Run by
    Jasper Gerritsen

    See if you can join NCT06118723 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.